Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Research And Development Expense of $145.64 million for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +75.2% in Research And Development Expense from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $13.82 million | Q3 2017: $5.21 million | Q1 2018: $7.85 million | Q2 2018: $9.68 million | Q3 2018: $11.42 million | Q1 2019: $10.54 million | Q2 2019: $13.43 million | Q3 2019: $16.52 million | Q1 2020: $13.96 million | Q2 2020: $12.61 million | Q3 2020: $11.79 million | Q1 2021: $11.73 million | Q2 2021: $11.13 million | Q3 2021: $10.80 million | Q1 2022: $16.55 million | Q2 2022: $11.60 million | Q3 2022: $7.22 million | Q1 2023: $5.85 million | Q2 2023: $10.25 million | Q3 2023: $7.96 million | Q1 2024: $13.08 million | Q2 2024: $18.07 million | Q3 2024: $25.54 million | Q1 2025: $27.00 million | Q2 2025: $26.25 million | Q3 2025: $32.49 million.
- Over the full 10 years of available data (2016 to 2025), Dianthus Therapeutics, Inc. /DE/'s Research And Development Expense has grown by 2,418.8%.
- Historical annual values: Fiscal year 2025: $145.64 million | Fiscal year 2024: $83.11 million | Fiscal year 2023: $32.84 million | Fiscal year 2022: $29.38 million | Fiscal year 2021: $46.77 million | Fiscal year 2020: $50.62 million | Fiscal year 2019: $59.21 million | Fiscal year 2018: $41.34 million | Fiscal year 2017: $27.90 million | Fiscal year 2016: $5.78 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: